Etiology of Atherosclerosis Flashcards
3 stages
fatty streak formation, plaque formation, plaque disruption
fatty streak formation
fatty yellow discolorations on the arterial inner surface that neither protrude into the lumen nor disrupt blood flow
plaque formation
arterial fatty streaks increase in size due to the inflammatory response as the lipid deposits accumulate
plaque disruption
as plaques grow in size their lipid cores become large which causes foam cell death, which leads to plaque necrosis, instability and increased potential for thrombogenesis.
modifiable risk factors for hyperlipidemia
obesity, hypertension, diabetes, smoking, and physical inactivity
biomarkers
C-reactive protein, hyperhomocysteinemia, and lipoprotein(a)
Risk enhancing factors
Family hx of premature ASCVD; primary hypercholesterolemia; metabolic syndrome; chronic kidney disease; chronic inflammatory conditions; history of POI, high risk race/ethnicity; persistently elevated primary hypertriglyceridemia and/or other biomarkers associated with increased risk
elevated hcCRP
2.0 and above
elevated Lp(a)
50mg/dL and above or 125 nmol/L and above (order for fam hx premature ASCVD)
elevated Apo B
130 mg/dL (order if triglyceride is 200 or more)
Stratification of hsCRP for ASCVD risk
Low risk: < 1 mg/L
Moderate risk: 1–3 mg/L
High risk: > 3 mg/L
An hsCRP level >10 mg/L has been observed in acute plaque rupture, which may lead
to thrombosis
Homocysteine levels
High homocysteine blood levels (greater than 15
mcmol/L) are associated with increased oxidative
stress and secretion of proinflammatory factors.
Both mechanisms stimulate smooth cell proliferation and accelerate atherosclerosis.
Importance of lipoprotein(a)
a subtype of LDL that
includes apoprotein A (Apo A) in its structure.
Role of lipoprotein(a) in atherosclerosis
(1) inhibition
of fibrinolysis (2) enhanced capacity to traverse the arterial endothelium (3) low affinity
for the LDL-receptor mediated clearance from circulation
Using lipoprotein(a) in treatment decisions
If > than 30 mg/dL in patients with an elevated total cholesterol:HDL ratio (> 5.5) or other major RFs risk indicates the need for a more aggressive therapy to further lower LDL